Glycemic control and cardiovascular disease

What's a doctor to do?

Preeti Kishore, Sharon H. Kim, Jill P. Crandall

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.

Original languageEnglish (US)
Pages (from-to)255-264
Number of pages10
JournalCurrent Diabetes Reports
Volume12
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Cardiovascular Diseases
Mortality
Type 2 Diabetes Mellitus
Diabetes Mellitus
Morbidity
Therapeutics

Keywords

  • Cardiovascular disease
  • Glycemic control
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Glycemic control and cardiovascular disease : What's a doctor to do? / Kishore, Preeti; Kim, Sharon H.; Crandall, Jill P.

In: Current Diabetes Reports, Vol. 12, No. 3, 06.2012, p. 255-264.

Research output: Contribution to journalArticle

Kishore, Preeti ; Kim, Sharon H. ; Crandall, Jill P. / Glycemic control and cardiovascular disease : What's a doctor to do?. In: Current Diabetes Reports. 2012 ; Vol. 12, No. 3. pp. 255-264.
@article{eefda079e60b4ab9a3d2ad7759b40ae6,
title = "Glycemic control and cardiovascular disease: What's a doctor to do?",
abstract = "Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.",
keywords = "Cardiovascular disease, Glycemic control, Type 2 diabetes",
author = "Preeti Kishore and Kim, {Sharon H.} and Crandall, {Jill P.}",
year = "2012",
month = "6",
doi = "10.1007/s11892-012-0268-5",
language = "English (US)",
volume = "12",
pages = "255--264",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Glycemic control and cardiovascular disease

T2 - What's a doctor to do?

AU - Kishore, Preeti

AU - Kim, Sharon H.

AU - Crandall, Jill P.

PY - 2012/6

Y1 - 2012/6

N2 - Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.

AB - Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.

KW - Cardiovascular disease

KW - Glycemic control

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84861095994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861095994&partnerID=8YFLogxK

U2 - 10.1007/s11892-012-0268-5

DO - 10.1007/s11892-012-0268-5

M3 - Article

VL - 12

SP - 255

EP - 264

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 3

ER -